Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting
April 14 2015 - 8:00AM
Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today
announced that two preclinical abstracts and one clinical
translation abstract are scheduled for poster presentations at the
106th Annual Meeting of the American Association for Cancer
Research (AACR), to be held April 18-22, 2015 in Philadelphia,
Pennsylvania. Data to be presented include studies investigating
the therapeutic potential of Peregrine's phosphatidylserine
(PS)-targeting antibodies when administered in combination
treatment regimens with approved and developmental cancer
immunotherapies and translation data in patients with lung cancer.
Peregrine's lead PS-targeting antibody, bavituximab, is in Phase
III development for the treatment of second-line non-small lung
cancer (the "SUNRISE trial") along with several
investigator-sponsored trials evaluating other treatment
combinations and additional oncology indications.
Abstract details:
Abstract Number: 274
Presentation Title: Bavituximab modulates tumor
microenvironment and activates CD8+ tumor infiltrating lymphocytes
in a patient-derived 3D ex vivo system of lung cancer
Presentation Time: Sunday, April 19, 2015, 1:00 PM
- 5:00 PM Eastern Daylight Time Location:
Section 13 Poster Board Number: 2
Author Block: Soner Altiok1, Melanie
Mediavilla-Valera2, Jenny Kreahling2, David Noyes2, Tiffany N.
Razabdouski2, Nikoletta L. Kallinteris3, Joseph Shan3, Scott
Antonia2. 1Nilogen Oncosystems, Tampa, FL; 2Moffitt Cancer Center,
Tampa, FL; 3Peregrine Pharmaceuticals, Inc, Tustin, CA
Abstract Number: 252 Presentation
Title: Antibody-mediated phosphatidylserine blockade
significantly enhances the efficacy of immune checkpoint blockades
in K1735 and B16 mouse melanoma models Presentation
Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern
Daylight Time Location: Section 12
Poster Board Number: 10 Author
Block: Bruce Freimark1, Jian Gong1, Dan Ye2, Rolf
Brekken2, Shen Yin1, Jeff Hutchins1, Van Nguyen1, Chris Hughes3,
Xianming Huang2. 1Peregrine Pharmaceuticals, Inc, Tustin, CA; 2UT
Southwestern Medical Center, Dallas, TX; 3University of California,
Irvine, Irvine, CA
Abstract Number: 4289 Presentation
Title: Targeting of phosphatidylserine by monoclonal
antibodies enhances the activity of immune checkpoint inhibitors in
breast tumors Presentation Time: Tuesday,
April 21, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 24 Poster Board
Number: 19 Author Block: Jian Gong,
Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freimark. Peregrine
Pharmaceuticals, Inc., Tustin, CA
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials for the
treatment and diagnosis of cancer. The company's lead immunotherapy
candidate, bavituximab is in Phase III development for the
treatment of second-line non-small lung cancer (the "SUNRISE
trial") along with several investigator-sponsored trials evaluating
other treatment combinations and additional oncology indications.
The company is also advancing a molecular imaging agent,
124I-PGN650, in an exploratory clinical trial for the imaging of
multiple solid tumor types. Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024